Literature DB >> 27059723

Improved micro-distribution of antibody-photon absorber conjugates after initial near infrared photoimmunotherapy (NIR-PIT).

Tadanobu Nagaya1, Yuko Nakamura1, Kazuhide Sato1, Toshiko Harada1, Peter L Choyke1, Hisataka Kobayashi2.   

Abstract

Near infrared photoimmunotherapy (NIR-PIT), a targeted cancer therapy which uses an antibody-photo absorber conjugate (APC) and near infrared light exposure, dramatically improves nano-drug delivery into treated tumor beds due to enhanced vascular permeability. We investigated the micro-distribution of APCs in a variety of NIR-PIT treated tumors. Either cetuximab (cet) or trastuzumab (tra) conjugated with IR700 (cet-tra-IR700) was administered, as appropriate, to each mouse model of tumor. Tumor-bearing mice implanted with A431-GFP, MDAMB468-GFP, 3T3Her2-GFP or N87-GFP were separated into 5 groups: group 1=no treatment; group 2=cet-tra-IR700 i.v., no light exposure; group 3=cet-tra-IR700 i.v., NIR light exposure; group 4=cet-tra-IR700 i.v. and additional cet-tra-IR700 i.v. at 24h but no light exposure; group 5=cet-tra-IR700 i.v., NIR light exposure and additional cet-tra-IR700 i.v. immediately after NIR but no additional NIR light exposure. In vivo, ex vivo and microscopic fluorescence imaging was performed. Fluorescence from the surface of the tumor (s-tumor) was compared to fluorescence from deeper areas of the tumor (d-tumor). In general, there was no significant difference in the fluorescence intensity of GFP in the tumors among all groups, however the highest IR700 fluorescence intensity was consistently shown in group 5 tumors due to added APC after NIR-PIT. Fluorescence microscopy in all tumor types demonstrated that GFP relative fluorescence intensity (RFI) in s-tumor was significantly lower in group 3 and 5 (NIR-PIT groups) than in group 1, 2, and 4 (no NIR-PIT) yet there was no significant difference in d-tumor RFI among all groups. IR700 fluorescent RFI in the d-tumor was highest in group 5 (NIR-PIT+additional APC) compared to the other groups. Cell killing after NIR-PIT was primarily on the surface, however, APCs administered immediately after NIR-PIT penetrated deeper into tissue resulting in improved cell killing after a 2nd NIR-PIT session. This phenomenon is explained by increased vascular permeability immediately after NIR-PIT. Published by Elsevier B.V.

Entities:  

Keywords:  Drug delivery; Enhanced permeability and retention effect; Micro distribution; Near infrared light; Photoimmunotherapy

Mesh:

Substances:

Year:  2016        PMID: 27059723      PMCID: PMC4893891          DOI: 10.1016/j.jconrel.2016.04.003

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  25 in total

1.  Cancer cells mimic in vivo spatial-temporal cell-cycle phase distribution and chemosensitivity in 3-dimensional Gelfoam® histoculture but not 2-dimensional culture as visualized with real-time FUCCI imaging.

Authors:  Shuya Yano; Shinji Miwa; Sumiyuki Mii; Yukihiko Hiroshima; Fuminaru Uehara; Hiroyuki Kishimoto; Hiroshi Tazawa; Ming Zhao; Michael Bouvet; Toshiyoshi Fujiwara; Robert M Hoffman
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 2.  Mechanisms of tumor progression.

Authors:  P C Nowell
Journal:  Cancer Res       Date:  1986-05       Impact factor: 12.701

3.  Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts.

Authors:  Robert M Hoffman
Journal:  Nat Rev Cancer       Date:  2015-08       Impact factor: 60.716

4.  Subcellular imaging in the live mouse.

Authors:  Robert M Hoffman; Meng Yang
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

Review 5.  Drug penetration in solid tumours.

Authors:  Andrew I Minchinton; Ian F Tannock
Journal:  Nat Rev Cancer       Date:  2006-08       Impact factor: 60.716

6.  Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation.

Authors:  Hisataka Kobayashi; Koen Reijnders; Sean English; Alexander T Yordanov; Diane E Milenic; Anastasia L Sowers; Deborah Citrin; Murali C Krishna; Thomas A Waldmann; James B Mitchell; Martin W Brechbiel
Journal:  Clin Cancer Res       Date:  2004-11-15       Impact factor: 12.531

7.  The characterization of blood flow changes in mouse tumor during Photofrin-based photodynamic therapy by using the color Doppler ultrasonography.

Authors:  Karmen Dubreta; Sinisa Ivankovic; Arijana Lovrencic-Huzjan; Marijana Bosnar-Puretic; Ranko Stojkovic; Mislav Jurin
Journal:  Oncol Rep       Date:  2009-11       Impact factor: 3.906

8.  Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors.

Authors:  Kohei Sano; Takahito Nakajima; Peter L Choyke; Hisataka Kobayashi
Journal:  ACS Nano       Date:  2012-12-18       Impact factor: 15.881

9.  Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice.

Authors:  M Gil; M Bieniasz; M Seshadri; D Fisher; M J Ciesielski; Y Chen; R K Pandey; D Kozbor
Journal:  Br J Cancer       Date:  2011-10-11       Impact factor: 7.640

10.  Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen.

Authors:  Tadanobu Nagaya; Kazuhide Sato; Toshiko Harada; Yuko Nakamura; Peter L Choyke; Hisataka Kobayashi
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

View more
  8 in total

1.  Molecularly Targeted Cancer Combination Therapy with Near-Infrared Photoimmunotherapy and Near-Infrared Photorelease with Duocarmycin-Antibody Conjugate.

Authors:  Tadanobu Nagaya; Alexander P Gorka; Roger R Nani; Shuhei Okuyama; Fusa Ogata; Yasuhiro Maruoka; Peter L Choyke; Martin J Schnermann; Hisataka Kobayashi
Journal:  Mol Cancer Ther       Date:  2017-12-13       Impact factor: 6.261

2.  3D mesoscopic fluorescence tomography for imaging micro-distribution of antibody-photon absorber conjugates during near infrared photoimmunotherapy in vivo.

Authors:  Qinggong Tang; Tadanobu Nagaya; Yi Liu; Hannah Horng; Jonathan Lin; Kazuhide Sato; Hisataka Kobayashi; Yu Chen
Journal:  J Control Release       Date:  2018-04-16       Impact factor: 9.776

3.  Near-Infrared Photoimmunotherapy Targeting Prostate Cancer with Prostate-Specific Membrane Antigen (PSMA) Antibody.

Authors:  Tadanobu Nagaya; Yuko Nakamura; Shuhei Okuyama; Fusa Ogata; Yasuhiro Maruoka; Peter L Choyke; Hisataka Kobayashi
Journal:  Mol Cancer Res       Date:  2017-06-06       Impact factor: 5.852

4.  Real-time monitoring of microdistribution of antibody-photon absorber conjugates during photoimmunotherapy in vivo.

Authors:  Qinggong Tang; Tadanobu Nagaya; Yi Liu; Jonathan Lin; Kazuhide Sato; Hisataka Kobayashi; Yu Chen
Journal:  J Control Release       Date:  2017-06-08       Impact factor: 9.776

5.  Cancer neovasculature-targeted near-infrared photoimmunotherapy (NIR-PIT) for gastric cancer: different mechanisms of phototoxicity compared to cell membrane-targeted NIR-PIT.

Authors:  Takashi Nishimura; Makoto Mitsunaga; Kimihiro Ito; Hisataka Kobayashi; Masayuki Saruta
Journal:  Gastric Cancer       Date:  2019-07-13       Impact factor: 7.370

Review 6.  Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?

Authors:  Yuko Nakamura; Ai Mochida; Peter L Choyke; Hisataka Kobayashi
Journal:  Bioconjug Chem       Date:  2016-09-02       Impact factor: 4.774

7.  Near infrared photoimmunotherapy of B-cell lymphoma.

Authors:  Tadanobu Nagaya; Yuko Nakamura; Kazuhide Sato; Toshiko Harada; Peter L Choyke; Hisataka Kobayashi
Journal:  Mol Oncol       Date:  2016-07-29       Impact factor: 6.603

8.  Implantable wireless powered light emitting diode (LED) for near-infrared photoimmunotherapy: device development and experimental assessment in vitro and in vivo.

Authors:  Kohei Nakajima; Toshihiro Kimura; Hideo Takakura; Yasuo Yoshikawa; Atsushi Kameda; Takayuki Shindo; Kazuhide Sato; Hisataka Kobayashi; Mikako Ogawa
Journal:  Oncotarget       Date:  2018-04-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.